HQ: Chicago, IL
Leadership: Jeffrey Aronin, Rama Ranganathan, M.D., Ph.D., Mike Gamson
Website: evozyne.com
Opportunity: Design and build novel synthetic proteins that address historically unsolvable problems in healthcare and sustainability.
Vision: Leverage AI and molecular engineering to design customized proteins that address some of the toughest challenges in human health and sustainability.
Status: Active
> First partnered with Valor in April 2020.
> Evozyne's synthetic biology platform is based on over 20 years of fundamental research on how and why proteins are built through the process of evolution.
> Reductions in gene sequencing costs, an explosion of genomic data, and advances in artificial intelligence are driving an acceleration in the "Bio Revolution."
> Synthetic biology is expected to drive over $1.8 trillion of long-term economic impact.
